Abstract

BackgroundThe digitization of healthcare data, resulting from the increasingly widespread adoption of electronic health records, has greatly facilitated its analysis by computational methods and thereby enabled large-scale secondary use thereof. This can be exploited to support public health activities such as pharmacovigilance, wherein the safety of drugs is monitored to inform regulatory decisions about sustained use. To that end, electronic health records have emerged as a potentially valuable data source, providing access to longitudinal observations of patient treatment and drug use. A nascent line of research concerns predictive modeling of healthcare data for the automatic detection of adverse drug events, which presents its own set of challenges: it is not yet clear how to represent the heterogeneous data types in a manner conducive to learning high-performing machine learning models.MethodsDatasets from an electronic health record database are used for learning predictive models with the purpose of detecting adverse drug events. The use and representation of two data types, as well as their combination, are studied: clinical codes, describing prescribed drugs and assigned diagnoses, and measurements. Feature selection is conducted on the various types of data to reduce dimensionality and sparsity, while allowing for an in-depth feature analysis of the usefulness of each data type and representation.ResultsWithin each data type, combining multiple representations yields better predictive performance compared to using any single representation. The use of clinical codes for adverse drug event detection significantly outperforms the use of measurements; however, there is no significant difference over datasets between using only clinical codes and their combination with measurements. For certain adverse drug events, the combination does, however, outperform using only clinical codes. Feature selection leads to increased predictive performance for both data types, in isolation and combined.ConclusionsWe have demonstrated how machine learning can be applied to electronic health records for the purpose of detecting adverse drug events and proposed solutions to some of the challenges this presents, including how to represent the various data types. Overall, clinical codes are more useful than measurements and, in specific cases, it is beneficial to combine the two.

Highlights

  • The digitization of healthcare data, resulting from the increasingly widespread adoption of electronic health records, has greatly facilitated its analysis by computational methods and thereby enabled large-scale secondary use thereof

  • Results we report on the predictive performance, in terms of accuracy and area under ROC curve (AUC), of models generated with the random forest algorithm that was provided with various representations of 27 clinical datasets, each one containing a different data type and representation, as well as combinations of these - with and without feature selection

  • This study investigated the use of various types of structured electronic health records (EHRs) data - clinical measurements and clinical codes - both in isolation and in combination, to build machine learning models for adverse drug events (ADEs) detection

Read more

Summary

Introduction

The digitization of healthcare data, resulting from the increasingly widespread adoption of electronic health records, has greatly facilitated its analysis by computational methods and thereby enabled large-scale secondary use thereof This can be exploited to support public health activities such as pharmacovigilance, wherein the safety of drugs is monitored to inform regulatory decisions about sustained use. The primary resources involved in pharmacovigilance are clinical trials, spontaneous reports and longitudinal healthcare databases [6] The use of these can be divided into pre-marketing and post-marketing pharmacovigilance activities. In the pre-marketing stage, prior to the launch of a drug, clinical trials are used to gather information on both the efficacy and safety of a drug Such a source of information comes with two inherent limitations, namely small samples of participants and short study duration. As a result of these limitations, the need for alternative, complementary data sources is duly being acknowledged

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call